Middle East & Africa Influenza Vaccines Market

The Middle East & Africa influenza vaccines market is expected to grow from US$ 374.35 million in 2022 to US$ 533.85 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination to Bolster Middle East & Africa Influenza Vaccines Market During Forecast Period

Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats in the Middle East & Africa. Thus, strong pipeline candidates for influenza vaccines are the latest trend in the Middle East & Africa influenza vaccines market.

Market Overview

The Middle East & Africa influenza vaccines market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. In 2022, South Africa was the largest market for influenza vaccines in the region. The market for influenza vaccines in the Middle East & Africa is anticipated to grow at a CAGR of 6.1% during the forecast period. The influenza vaccines market is expected to grow due to the rising population base, increasing cases of influenza, growing research studies across the region, and increasing healthcare facilities. 

Middle East & Africa Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Influenza Vaccines Strategic Insights

Strategic insights for the Middle East & Africa Influenza Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Influenza Vaccines Report Scope

Middle East & Africa Influenza Vaccines Regional Insights

The geographic scope of the Middle East & Africa Influenza Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Middle East & Africa influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country. 

Based on vaccine type, the Middle East & Africa influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Middle East & Africa influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Middle East & Africa influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Middle East & Africa influenza vaccines market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the Middle East & Africa influenza vaccines market.